← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Quadriga Biosciences, Inc.
Los Altos, CA
$8,316,758
Total funding
3
Grants
Funding over time
peak $2.4M · FY2013–25$2.5M$1.9M$1.3M$625K$0
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$8,316,758 · 3
By mechanism
R44$8,028,659 · 2
R43$288,099 · 1
Investigators at Quadriga Biosciences, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
All-Time
Most funded here, all years
Largest grants
Phase 1b/2a Trial of QBS-72S for the Treatment of Newly Diagnosed Glioblastoma Multiforme in Patients with Unmethylated MGMT Promoters$1,368,236
R44 · FY2021 · CA
Phase 1b/2a Trial of QBS-72S for the Treatment of Newly Diagnosed Glioblastoma Multiforme in Patients with Unmethylated MGMT Promoters$1,324,080
R44 · FY2023 · CA
Phase 1b/2a Trial of QBS-72S for the Treatment of Newly Diagnosed Glioblastoma Multiforme in Patients with Unmethylated MGMT Promoters$1,307,447
R44 · FY2025 · CA
QBS10072S for the Treatment of Brain Metastatic Triple-Negative Breast Cancer$1,053,136
R44 · FY2021 · CA
Novel targeted Chemotherapeutics for Gliobastoma$1,018,590
R44 · FY2017 · CA
Novel targeted Chemotherapeutics for Gliobastoma$968,230
R44 · FY2018 · CA
QBS10072S for the Treatment of Brain Metastatic Triple-Negative Breast Cancer$702,470
R44 · FY2024 · CA
Novel Chemotherapeutics for Brain Tumors$288,099
R43 · FY2013 · CA
QBS10072S for the Treatment of Brain Metastatic Triple-Negative Breast Cancer$286,470
R44 · FY2023 · CA